Y-o-y growth in the total revenue represents increased potential for the company to increase their market share.Total revenue for the current quarter is compared with the same quarter of previous year to reduce the effects of seasonality

Decreasing Total Revenue

Y-o-y growth in the net income represents increased profitability of the company.Net profit for the current quarter is compared with the same quarter of previous year to reduce the effects of seasonality

Decreasing Net Profit

Increasing EBITDA margin indicates increased profit efficiency without taking into account financial, accounting or tax implications

Constant EBITDA Margin

Increasing Net profit margins indicates the increasing profit to the shareholders with each unit of revenue

Constant Net Profit Margin

Y-o-y growth in the EBITDA represents how efficiently the company manages its expenses.EBITDA for the current quarter is compared with the same quarter of previous year to reduce the effects of seasonality

Decreasing EBIDTA

Gufic Biosciences Limited has informed the Exchange about Investor Presentation

Investor Presentation

Price return has been average, nothing exciting

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Average profitability - not good, not bad

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Gufic Biosciences Limited manufactures pharmaceuticals, medicinal chemicals and botanical products. The Company's segments include Formulations, Bulk Drugs and Consumer.

Gufic Biosciences Ltd

Gufic Biosciences Ltd

Scorecard

Financial Statements

What is an income statement?

Income Statement

Company Updates